Deux Rives Capital
All closed deals
Closed November 2025

VESSEL THERAPEUTICS

Peptide delivery across the blood–brain barrier.

Listed May 2025 · 188 days listing to close

RaisedCHF 3.5M
RoundSeed
SectorBiotech

What actually happened

A seven-angel syndicate is administratively heavier than one fund, and most founders cannot run it alone. The value here was structural: one convertible instrument, one set of terms, two closes six weeks apart, and a single point of contact so the founders kept working on the science rather than on the cap table.

What Deux Rives did

  • Structured a single instrument across eight parties.
  • Ran the syndicate process and the second close.
  • Prepared the scientific pack for non-specialist angels.
  • Set up reporting cadence post-close on the Trinity stack.

Deal shape

InstrumentConvertible loan, capped
CapCHF 14M
BoardObserver seat
SyndicateEight parties, two closes

Syndicate

LeadSyndicate of seven business angels, life-science operators
Co-investorCantonal innovation vehicle

Investor identities are described by type only. That is deliberate and permanent.